SciClone Pharma launches $281m Hong Kong IPO

Pharma_drugs_adobe_575x375.jpg
By Jonathan Breen
19 Feb 2021

SciClone Pharmaceuticals, which manufactures a possible treatment for the coronavirus, hit the IPO market with a HK$2.18bn ($281.2m) offering on Friday.

The company is working with sponsors CICC, Credit Suisse and Morgan Stanley. The trio launched bookbuilding after premarketing the deal before the Chinese New Year holidays. ABC International, BOC International and Nomura are global co-ordinators, while Zhongtai International is a bookrunner and lead manager.

SciClone is listing 115.98m shares, ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial